BEUDAMED
    FDA Adverse Event Injury Summary report: N

    VENT RES TR RICKHAM LG BA

    MDR report key: 15971901 · Received December 13, 2022

    Report

    Report Number
    3013886523-2022-00568
    Event Type
    Injury
    Date Received
    December 13, 2022
    Date of Event
    January 7, 2022
    Report Date
    April 27, 2023
    Manufacturer
    INTEGRA LIFESCIENCES SWITZERLAND SAR
    Product Code
    JXG
    UDI-DI
    10381780517771
    PMA / PMN Number
    K102961
    Adverse Event
    Yes
    Report Source
    Manufacturer report
    Reporter Occupation
    OTHER
    Health Professional
    N

    Narratives

    Additional Manufacturer Narrative · 0

    AN INVESTIGATION HAS BEEN INITIATED BASED ON THE REPORTED INFORMATION. UPON COMPLETION OF THE INVESTIGATION, A FOLLOW-UP REPORT WILL BE SUBMITTED.

    Additional Manufacturer Narrative · 0

    THE RICKHAM RESERVOIR (ID 821623) WAS NOT RETURNED FOR EVALUATION AND LOT NUMBER INFORMATION HAS NOT BEEN PROVIDED; THEREFORE, AN EVALUATION OF THE DEVICE COULD NOT BE PERFORMED, AND DEVICE HISTORY RECORD (DHR) COULD NOT BE REVIEWED. THE ROOT CAUSE(S) OF THE REPORTED ISSUE COULD NOT BE DETERMINED. IF ADDITIONAL RELEVANT INFORMATION BECOMES AVAILABLE IN THE FUTURE, THIS COMPLAINT WILL BE REOPENED, AND THE RESPECTIVE EVALUATION PERFORMED. TRENDS WILL BE MONITORED FOR THIS AND SIMILAR ISSUES. AT PRESENT, WE CONSIDER THIS COMPLAINT TO BE CLOSED.

    Description of Event or Problem · 0

    MEDWATCH (B)(4). CASE STUDY REPORT (BMRN) REFERRING TO A 7 YEAR-OLD MALE SUBJECT. AN INVESTIGATOR REPORTED THIS CASE FROM THE BIOMARIN SPONSORED STUDY, CERLIPONASE ALFA OBSERVATIONAL STUDY. THE SUBJECT'S PAST MEDICAL HISTORY INCLUDED: LIP ULCERATION AND COVID-19. THE SUBJECT'S CONCURRENT CONDITIONS INCLUDED: NEURONAL CEROID LIPOFUSCINOSIS, AUTISM SPECTRUM DISORDER, DYSARTHRIA, WHEELCHAIR USER, HEART RATE IRREGULAR, SEIZURE, AND DISCOMFORT. NO ALLERGIES WERE REPORTED. CONCOMITANT MEDICATION INCLUDED: ONDANSETRON, LIDOCAINE, VALPROATE. ON (B)(6) 2019, THE SUBJECT UNDERWENT IMPLANTATION OF AN INTRACEREBRAL VENTRICULOSTOMY (ICV) SET (CODMAN & SHURTLEFF, INC-RICKHAM; MODEL 82-1623) (LOT, CATALOG, SERIAL, AND UDI NUMBERS NOT REPORTED). ON (B)(6) 2019, THE SUBJECT INITIATED TREATMENT WITH BRINEURA (300 MILLIGRAM, QOW, ICV). THE LOT NUMBER FOR BRINEURA WAS L241207. THE MOST RECENT DOSE WAS ADMINISTERED ON (B)(6) 2022. ON (B)(6) 2022 AT 9:43, THE SUBJECT EXPERIENCED A GRADE 1 DEVICE RELATED INFECTION (DEVICE RELATED INFECTION) WITH A POSITIVE CSF RESULT THAT WAS CONFIRMED ON (B)(6) 2022. THE CSF CULTURE ON (B)(6) 2022 REVEALED FEW WHITE BLOOD CELLS AND NO ORGANISMS WERE SEEN; HOWEVER, ON (B)(6) 2022, THE RESULTS REVEALED RARE GRAM POSITIVE RODS - IN THIOGLYCOLATE BROTH ONLY. NO TREATMENT FOR THE EVENT WAS REPORTED. NO ACTION WAS TAKEN WITH BRINEURA DUE TO THE EVENT. THE OUTCOME OF THE EVENT WAS REPORTED AS RECOVERING/RESOLVING. BIOMARIN PHARMACEUTICAL HAS ASSESSED THE EVENT AS MEDICALLY SIGNIFICANT. THE INVESTIGATOR ASSESSED THE EVENT OF DEVICE RELATED INFECTION AS NOT RELATED TO TREATMENT WITH BRINEURA. ACCORDING TO THE INVESTIGATOR, OTHER ETIOLOGICAL FACTORS INCLUDED THE DEVICE. ADDITIONAL INFORMATION RECEIVED ON 27-JAN-2022: THE CSF OBTAINED ON (B)(6) 2022 WAS CONFIRMED NEGATIVE. HOWEVER, THE WBC CELL COUNT WAS 995 (UNITS NOT REPORTED) REFERENCE RANGE 0-5 AND THE TOTAL PROTEIN WAS 139 (UNITS NOT REPORTED) REFERENCE RANGE 12-60, WHICH WERE BOTH ABNORMAL AND CONSIDERED CLINICALLY SIGNIFICANT. THE SUBJECT WAS ADMITTED TO THE HOSPITAL FOR TREATMENT WITH INTRATHECAL VANCOMYCIN AND MONITORING OF HIS HEALTH CONDITION AFTER HIS INJECTION OF BRINEURA. THE SERIOUS CRITERIA OF THE EVENT WAS UPDATED BY THE INVESTIGATOR FROM MEDICALLY SIGNIFICANT TO HOSPITALIZATION. THE INVESTIGATOR UPDATED THE OUTCOME OF THE EVENT FROM RECOVERING/RESOLVING TO RECOVERED/RESOLVED ON (B)(6) 2022 AT 09:56. THE SUBJECT WAS DISCHARGED ON (B)(6) 2022 WITHOUT OTHER ISSUES. AN ADDITIONAL CSF OBTAINED ON (B)(6) 2022 WAS NEGATIVE. THE WBC CELL COUNT WAS 774 (UNITS NOT REPORTED) REFERENCE RANGE 0-5 AND WAS CONSIDERED ABNORMAL, WHICH WAS CLINICALLY SIGNIFICANT. ADDITIONAL INFORMATION RECEIVED ON 08-FEB-2022: THE OUTCOME DATE OF THE EVENT WAS UPDATED BY THE INVESTIGATOR FROM (B)(6) 2022 AT 9:56 TO (B)(6) 2022. ADDITIONAL INFORMATION RECEIVED ON 18-APR-2022: THE OUTCOME DATE OF THE EVENT WAS UPDATED BY THE INVESTIGATOR FROM 23-JAN-2022 TO 04-FEB-2022. ADDITIONAL INFORMATION RECEIVED ON 25-JUL-2022: THE SUBJECT'S CONCOMITANT MEDICATIONS ADDITIONALLY INCLUDED: CALCIUM GLUCONATE/MAGNESIUM CARBONATE/POTASSIUM CHLORIDE/SODIUM CHLORIDE, DIAZEPAM, SODIUM CHLORIDE. ADDITIONAL INFORMATION RECEIVED ON 18-NOV-2022: THE SUBJECT'S PAST MEDICAL HISTORY INCLUDED: COVID-19. THE SUBJECT'S CONCURRENT CONDITIONS INCLUDED: COVID-19. THE FIRST DOSE OF THE STUDY DATE WAS UPDATED FROM 17-MAY-2019 TO 21-AUG-2020. THE SEVERITY OF THE EVENT WAS UPDATED BY THE INVESTIGATOR FROM GRADE 1 TO GRADE 3. CASE COMMENT: THE PATIENT EXPERIENCED DEVICE RELATED INFECTION, WHICH IS A KNOWN COMPLICATION OF ICV DEVICE USE. THE CAUSALITY OF EVENT IS ASSESSED AS NOT RELATED TO BRINEURA.

    Description of Event or Problem · 0

    N/A.

    Devices

    Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
    2136964 VENT RES TR RICKHAM LG BA RESERVOIRS JXG INTEGRA LIFESCIENCES SWITZERLAND SAR 821621 L241207 10381780517771

    Patients

    Seq Age Sex Outcome Treatment
    1 7 YR Male ACETAMINOPHEN (ONGOING)| CLOBAZAM (ONGOING)| DEPAKOTE (09/2018 TO UNKNOWN DATE)| DIASTAT ACUDIAL (DIAZEPAM) (ONGOING)| LIDOCAINE (ONGOING)| MIRALAX (MACROGOL 3350) (ONGOING)| ONDANSETRON (ONGOING)| SODIUM CHLORIDE (TO UNK DATE)| TOPIRAMATE (ONGOING)| VALTOCO (DIAZEPAM) (TO UNK DATE)| ZONEGRAN (ZONISAMIDE)| ZONEGRAN (ZONISAMIDE) (ONGOING)| ZYRTEC (ONGOING)